Sapiens launches Sapiens Brain insurance-native AI foundation for SapiensAIP
Bitget2026/10/06 14:03Sapiens International Corporation NV launched Sapiens Brain to underpin its SapiensAIP platform, aiming to accelerate AI adoption across insurers. Product targets a competitive edge through more reliable, explainable AI decisioning suited to regulated insurance workflows, supporting enterprise-scale deployment. Design aims to shorten delivery cycles for new AI capabilities versus traditional core-system releases, potentially speeding customer modernization programs. Positioned to shift insurer operating models by moving routine work to AI agents, freeing staff for higher-value judgment decisions in key functions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sapiens International Corporation NV published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Sapiens International Corporation NV launched Sapiens Brain to underpin its SapiensAIP platform, aiming to accelerate AI adoption across insurers.
- Product targets a competitive edge through more reliable, explainable AI decisioning suited to regulated insurance workflows, supporting enterprise-scale deployment.
- Design aims to shorten delivery cycles for new AI capabilities versus traditional core-system releases, potentially speeding customer modernization programs.
- Positioned to shift insurer operating models by moving routine work to AI agents, freeing staff for higher-value judgment decisions in key functions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
